PMID- 33127210
OWN - NLM
STAT- MEDLINE
DCOM- 20211018
LR  - 20211018
IS  - 1532-9496 (Electronic)
IS  - 0887-7963 (Linking)
VI  - 34
IP  - 4
DP  - 2020 Oct
TI  - Human Leukocyte Antigen Alloimmunization and Alloimmune Platelet Refractoriness.
PG  - 250-257
LID - S0887-7963(20)30056-0 [pii]
LID - 10.1016/j.tmrv.2020.09.010 [doi]
AB  - Despite significant advancements in the production of platelet products, storage, 
      and transfusion, transfusion refractoriness remains a significant clinical 
      problem, affecting up to 14% of hematological patients receiving platelet 
      transfusions. Human leukocyte antigen (HLA) alloimmunization is a major cause of 
      immune platelet refractoriness, and its rate can be significantly reduced by 
      implementation of leukoreduction. Despite promising preclinical results, pathogen 
      reduction does not reduce HLA alloimmunization. Patients with HLA alloimmune 
      refractoriness are usually managed with HLA-selected platelet transfusions. In 
      this review, we describe the pathophysiology of HLA alloimmunization and 
      alloimmune refractoriness, as well as options to prevent and treat these 
      transfusion complications. We discuss the evidence supporting these options and 
      point out the outstanding gaps. Finally, we review the possible future directions 
      for prevention and treatment of alloimmune refractoriness.
CI  - Copyright (c) 2020 Elsevier Inc. All rights reserved.
FAU - Saris, Anno
AU  - Saris A
AD  - Department of Infectious Diseases, Leiden University Medical Centre, Leiden, the 
      Netherlands. Electronic address: a.saris@lumc.nl.
FAU - Pavenski, Katerina
AU  - Pavenski K
AD  - Departments of Medicine and Laboratory Medicine, St. Michael's Hospital and 
      University of Toronto, Toronto, Ontario, Canada. Electronic address: 
      Katerina.pavenski@unityhealth.to.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201007
PL  - United States
TA  - Transfus Med Rev
JT  - Transfusion medicine reviews
JID - 8709027
RN  - 0 (HLA Antigens)
RN  - 0 (Isoantibodies)
SB  - IM
MH  - Blood Platelets/*immunology
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Isoantibodies/*immunology
MH  - Platelet Count
MH  - *Platelet Transfusion
MH  - Thrombocytopenia/blood/immunology/*therapy
MH  - Treatment Failure
OTO - NOTNLM
OT  - Histocompatibility antigens class I
OT  - Platelet
OT  - Platelet transfusion
EDAT- 2020/11/01 06:00
MHDA- 2021/10/21 06:00
CRDT- 2020/10/31 05:26
PHST- 2020/06/27 00:00 [received]
PHST- 2020/09/13 00:00 [revised]
PHST- 2020/09/16 00:00 [accepted]
PHST- 2020/11/01 06:00 [pubmed]
PHST- 2021/10/21 06:00 [medline]
PHST- 2020/10/31 05:26 [entrez]
AID - S0887-7963(20)30056-0 [pii]
AID - 10.1016/j.tmrv.2020.09.010 [doi]
PST - ppublish
SO  - Transfus Med Rev. 2020 Oct;34(4):250-257. doi: 10.1016/j.tmrv.2020.09.010. Epub 
      2020 Oct 7.